A Novel Bromodomain Inhibitor Reverses HIV-1 Latency through Specific Binding with BRD4 to Promote Tat and P-TEFb Association

While combinatory antiretroviral therapy (cART) can effectively reduce HIV-1 viremia, it cannot eliminate HIV-1 infection. In the presence of cART, viral reservoirs remain latent, impeding the cure of HIV-1/AIDS. Recently, latency-reversing agents (LRAs) have been developed with the intent of purgin...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Huachao, Liu, Shuai, Jean, Maxime, Simpson, Sydney, Huang, He, Merkley, Mark, Hayashi, Tsuyoshi, Kong, Weili, Rodríguez-Sánchez, Irene, Zhang, Xiaofeng, Yosief, Hailemichael O., Miao, Hongyu, Que, Jianwen, Kobie, James J., Bradner, James, Santoso, Netty G., Zhang, Wei, Zhu, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461361/
https://www.ncbi.nlm.nih.gov/pubmed/28638377
http://dx.doi.org/10.3389/fmicb.2017.01035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461361/
https://www.ncbi.nlm.nih.gov/pubmed/28638377
http://dx.doi.org/10.3389/fmicb.2017.01035

Ejemplares similares